CA9 Primary Antibody
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human CA9 (AA: 37-186) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using CA9 mAb against human CA9 recombinant protein. (Expected MW is 42 kDa)
Figure 2: Western blot analysis using CA9 mAb against HEK293 (1) and CA9 (AA: 37-186)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 3: Western blot analysis using CA9 mouse mAb against A431 (1) and SW620 (2) cell lysate.
Figure 5: Immunohistochemical analysis of paraffin-embedded rectum cancer tissues using ZEB1 mouse mAb with DAB staining.
Figure 6: Immunohistochemical analysis of paraffin-embedded stomach tissues using CA9 mouse mAb with DAB staining.
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
|Description||Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and the only tumor-associated carbonic anhydrase isoenzyme known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12. |
|References (references)||1. Breast Cancer Res Treat. 2012 Nov;136(1):67-75. |
2. Histol Histopathol. 2011 Oct;26(10):1279-86.